{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T23:53:28Z","timestamp":1781481208121,"version":"3.54.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-49648-z","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T06:50:22Z","timestamp":1776667822000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics, laboratory measures, and quality of life as predictors of medication adherence in multiple myeloma"],"prefix":"10.1038","volume":"16","author":[{"given":"Nizar","family":"Abu Hamdeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5577-8499","authenticated-orcid":false,"given":"Mohammad","family":"Alnees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibraheem","family":"AbuAlrub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duha","family":"Najajra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Ewidat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Abu Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar","family":"Zahran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahya Z.","family":"Fraitekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdalaziz","family":"Darwish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Masu\u2019d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Dabash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwar","family":"Haj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Bakeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Khalili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kareem","family":"Ibraheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouraldin","family":"Hih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Atallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghaith","family":"Ghannam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nemat","family":"Ghannam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram","family":"Karama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laith","family":"El-Lahham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majdi","family":"Zaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loay","family":"Shaheen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majd","family":"Bayah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2336-3125","authenticated-orcid":false,"given":"Haitham","family":"Abu Khadija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"issue":"9","key":"49648_CR1","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1007\/s00277-020-04356-0","volume":"100","author":"LK Nielsen","year":"2021","unstructured":"Nielsen, L. K., Larsen, R. F., Jarlbaek, L., M\u00f6ller, S. & Jespersen, E. Health-related quality of life in patients with multiple myeloma participating in a multidisciplinary rehabilitation program. Ann. Hematol. 100 (9), 2311\u20132323 (2021).","journal-title":"Ann. Hematol."},{"issue":"12","key":"49648_CR2","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15 (12), e538\u2013e548 (2014).","journal-title":"Lancet Oncol."},{"issue":"18","key":"49648_CR3","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1182\/blood-2010-10-299529","volume":"117","author":"M Dimopoulos","year":"2011","unstructured":"Dimopoulos, M. et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 117 (18), 4701\u20134705 (2011).","journal-title":"Blood"},{"issue":"3","key":"49648_CR4","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3324\/haematol.2016.145078","volume":"102","author":"E Kastritis","year":"2017","unstructured":"Kastritis, E. et al. Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma. Haematologica 102 (3), 593\u2013599 (2017).","journal-title":"Haematologica"},{"key":"49648_CR5","unstructured":"Cancer & Today."},{"issue":"2","key":"49648_CR6","first-page":"127","volume":"2","author":"K Abu Ali","year":"2021","unstructured":"Abu Ali, K. & Access, O. The Hematological Malignancies Incidence in Gaza Strip. Palest SunText Rev. Biotechnol. 2 (2), 127 (2021).","journal-title":"Palest SunText Rev. Biotechnol."},{"issue":"3","key":"49648_CR7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos, M. A. et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Ann. Oncol. 32 (3), 309\u2013322 (2021).","journal-title":"Ann. Oncol."},{"issue":"8","key":"49648_CR8","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees, P. M. et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 136 (8), 936\u2013945 (2020).","journal-title":"Blood"},{"issue":"4","key":"49648_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s44228-022-00017-3","volume":"4","author":"A Ibrahim","year":"2022","unstructured":"Ibrahim, A. et al. Management of Multiple Myeloma in the Middle East: Unmet Needs, Challenges and Perspective. Clin. Hematol. Int. 4 (4), 127\u2013132 (2022).","journal-title":"Clin. Hematol. Int."},{"issue":"Supplement 1","key":"49648_CR10","doi-asserted-by":"publisher","first-page":"4734","DOI":"10.1182\/blood-2023-179416","volume":"142","author":"E Kastritis","year":"2023","unstructured":"Kastritis, E. et al. Bortezomib-Cyclophosphamide-Dexamethasone (VCD) Vs Bortezomib-Lenalidomide-Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma: A Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG). Blood 142 (Supplement 1), 4734\u20134734 (2023).","journal-title":"Blood"},{"issue":"12","key":"49648_CR11","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","volume":"21","author":"SK Kumar","year":"2023","unstructured":"Kumar, S. K. et al. Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc Netw. 21 (12), 1281\u20131301 (2023).","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"8","key":"49648_CR12","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar, S. V. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am. J. Hematol. 97 (8), 1086\u20131107 (2022).","journal-title":"Am. J. Hematol."},{"key":"49648_CR13","unstructured":"Gammal, M. & El Superiority of CyBorD Over VAD is More Evident in First than in Second Line Treatment of Multiple Myeloma OPEN ACCESS. (2019)."},{"key":"49648_CR14","doi-asserted-by":"crossref","unstructured":"Asfaw, A. A. et al. Barriers and Facilitators of Using Sensored Medication Adherence Devices in a Diverse Sample of Patients With Multiple Myeloma: Qualitative Study. JMIR cancer. 4(2), e12 (2018)","DOI":"10.2196\/cancer.9918"},{"key":"49648_CR15","doi-asserted-by":"crossref","unstructured":"Awwad, O., AlMuhaissen, S., Al-Nashwan, A. & AbuRuz, S. Translation and validation of the Arabic version of the Morisky, Green and Levine (MGL) adherence scale. PLoS One. 17(10), e0275778 (2022).","DOI":"10.1371\/journal.pone.0275778"},{"key":"49648_CR16","doi-asserted-by":"crossref","unstructured":"Cransac, A. et al. Adherence to immunomodulatory drugs in patients with multiple myeloma. PLoS One. 14(3), e0214446 (2019).","DOI":"10.1371\/journal.pone.0214446"},{"issue":"10","key":"49648_CR17","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1002\/cncr.34134","volume":"128","author":"EK O\u2019Donnell","year":"2022","unstructured":"O\u2019Donnell, E. K. et al. Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma. Cancer 128 (10), 1996\u20132004 (2022).","journal-title":"Cancer"},{"issue":"3","key":"49648_CR18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.5001\/omj.2011.38","volume":"26","author":"B Jimmy","year":"2011","unstructured":"Jimmy, B. & Jose, J. Patient medication adherence: measures in daily practice. Oman Med. J. 26 (3), 155\u2013159 (2011).","journal-title":"Oman Med. J."},{"issue":"14","key":"49648_CR19","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1001\/archinte.160.14.2101","volume":"160","author":"MR DiMatteo","year":"2000","unstructured":"DiMatteo, M. R., Lepper, H. S. & Croghan, T. W. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch. Intern. Med. 160 (14), 2101\u20132107 (2000).","journal-title":"Arch. Intern. Med."},{"issue":"10","key":"49648_CR20","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/0277-9536(95)00116-O","volume":"41","author":"S Ebrahim","year":"1995","unstructured":"Ebrahim, S. Clinical and public health perspectives and applications of health-related quality of life measurement. Soc. Sci. Med. 41 (10), 1383\u20131394 (1995).","journal-title":"Soc. Sci. Med."},{"issue":"10","key":"49648_CR21","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/0277-9536(95)00112-K","volume":"41","author":"The World Health Organization quality of life assessment (WHOQOL)","year":"1995","unstructured":"The World Health Organization quality of life assessment (WHOQOL). Position paper from the World Health Organization. Soc. Sci. Med. 41 (10), 1403\u20131409 (1995).","journal-title":"Soc. Sci. Med."},{"issue":"8","key":"49648_CR22","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1080\/17474086.2019.1634541","volume":"12","author":"M Martino","year":"2019","unstructured":"Martino, M. et al. Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials. Expert Rev. Hematol. 12 (8), 665\u2013684 (2019).","journal-title":"Expert Rev. Hematol."},{"issue":"11","key":"49648_CR23","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","volume":"43","author":"K Cocks","year":"2007","unstructured":"Cocks, K. et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur. J. Cancer. 43 (11), 1670\u20131678 (2007).","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"49648_CR24","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1182\/asheducation-2015.1.272","volume":"2015","author":"SV Rajkumar","year":"2015","unstructured":"Rajkumar, S. V. Evolving diagnostic criteria for multiple myeloma. Hematol. Am. Soc. Hematol. Educ. Progr. 2015 (1), 272\u2013278 (2015).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Progr"},{"issue":"9","key":"49648_CR25","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar, S. V. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 99 (9), 1802\u20131824 (2024).","journal-title":"Am. J. Hematol."},{"issue":"6","key":"49648_CR26","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","volume":"115","author":"I Hanamura","year":"2022","unstructured":"Hanamura, I. Multiple myeloma with high-risk cytogenetics and its treatment approach. Int. J. Hematol. 115 (6), 762\u2013777 (2022).","journal-title":"Int. J. Hematol."},{"issue":"12","key":"49648_CR27","doi-asserted-by":"publisher","first-page":"5849","DOI":"10.1007\/s00277-024-06129-5","volume":"103","author":"D Shah","year":"2024","unstructured":"Shah, D. et al. Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes. Ann. Hematol. 103 (12), 5849\u20135859 (2024).","journal-title":"Ann. Hematol."},{"issue":"3","key":"49648_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.6004\/jnccn.2018.7098","volume":"17","author":"JM Jacobs","year":"2019","unstructured":"Jacobs, J. M. et al. Patient Experiences With Oral Chemotherapy: Adherence, Symptoms, and Quality of Life. J. Natl. Compr. Canc Netw. 17 (3), 221\u2013228 (2019).","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"4","key":"49648_CR29","first-page":"279","volume":"49","author":"SM Belcher","year":"2022","unstructured":"Belcher, S. M. et al. ONS Guidelines\u2122 to Support Patient Adherence to Oral Anticancer Medications. Oncol. Nurs. Forum. 49 (4), 279\u2013295 (2022).","journal-title":"Oncol. Nurs. Forum"},{"issue":"3","key":"49648_CR30","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.clml.2018.01.006","volume":"18","author":"S Gupta","year":"2018","unstructured":"Gupta, S. et al. Assessing the Effect of Adherence on Patient-reported Outcomes and Out of Pocket Costs Among Patients With Multiple Myeloma. Clin Lymphoma. Myeloma Leuk. 18 (3), 210\u2013218 (2018).","journal-title":"Myeloma Leuk."},{"key":"49648_CR31","doi-asserted-by":"crossref","unstructured":"Sidorkiewicz, S., Tran, V. T., Cousyn, C., Perrodeau, E. & Ravaud, P. Development and validation of an instrument to assess treatment adherence for each individual drug taken by a patient. BMJ Open. 6(5), e010510 (2016).","DOI":"10.1136\/bmjopen-2015-010510"},{"key":"49648_CR32","doi-asserted-by":"crossref","unstructured":"Silveira, L. P. et al. NL, et al. Validation of an Instrument for Measuring Adherence to Treatment With Immunomodulators in Patients With Multiple Myeloma. Front. Pharmacol. 12, 651523 (2021).","DOI":"10.3389\/fphar.2021.651523"},{"issue":"1","key":"49648_CR33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","volume":"24","author":"DE Morisky","year":"1986","unstructured":"Morisky, D. E., Green, L. W. & Levine, D. M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med. Care. 24 (1), 67\u201374 (1986).","journal-title":"Med. Care"},{"issue":"8","key":"49648_CR34","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.clml.2025.02.005","volume":"25","author":"K Weisel","year":"2025","unstructured":"Weisel, K. et al. Health-Related Quality of Life in Patients With Relapsed\/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR Trial. Clin. Lymphoma Myeloma Leuk. 25 (8), 590\u2013605 (2025).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"49648_CR35","doi-asserted-by":"publisher","first-page":"S531","DOI":"10.1016\/j.jval.2019.09.676","volume":"22","author":"Z Ou","year":"2019","unstructured":"Ou, Z. PCN484 Systematic Review Of A Disease-Specific Patient-Reported Outcome Measure In Patients With Multiple Myeloma: Eortc Qlq-My20 Instrument Development And Validation. Value Heal. 22, S531 (2019).","journal-title":"Value Heal"},{"issue":"6","key":"49648_CR36","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s11136-012-0261-0","volume":"22","author":"HAS Huijer","year":"2013","unstructured":"Huijer, H. A. S., Sagherian, K. & Tamim, H. Validation of the Arabic version of the EORTC quality of life questionnaire among cancer patients in Lebanon. Qual. Life Res. 22 (6), 1473\u20131481 (2013).","journal-title":"Qual. Life Res."},{"key":"49648_CR37","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1146\/annurev.publhealth.23.100901.140546","volume":"23","author":"T Lumley","year":"2002","unstructured":"Lumley, T., Diehr, P., Emerson, S. & Chen, L. The importance of the normality assumption in large public health data sets. Annu. Rev. Public. Health. 23, 151\u2013169 (2002).","journal-title":"Annu. Rev. Public. Health"},{"key":"49648_CR38","unstructured":"Field, A. Discovering statistics using IBM SPSS statistics. ;1110. (2024)."},{"issue":"11","key":"49648_CR39","first-page":"4265","volume":"27","author":"S Feiten","year":"2019","unstructured":"Feiten, S. et al. High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology\/oncology group practices in Germany. Support Care Cancer. 27 (11), 4265\u20134271 (2019).","journal-title":"Support Care Cancer"},{"key":"49648_CR40","doi-asserted-by":"crossref","unstructured":"Tesfaye, W. H. et al. Medication Adherence, Burden and Health-Related Quality of Life in Adults with Predialysis Chronic Kidney Disease: A Prospective Cohort Study. Int. J. Environ. Res. Public. Health 17(1), 371 (2020).","DOI":"10.3390\/ijerph17010371"},{"issue":"3","key":"49648_CR41","doi-asserted-by":"publisher","first-page":"E243854","DOI":"10.1001\/jamanetworkopen.2024.3854","volume":"7","author":"JD Peipert","year":"2024","unstructured":"Peipert, J. D. et al. Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma. JAMA Netw. open. 7 (3), E243854 (2024).","journal-title":"JAMA Netw. open."},{"key":"49648_CR42","doi-asserted-by":"crossref","unstructured":"Collins, G. S., Reitsma, J. B., Altman, D. G. & Moons, K. G. M. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 350, g7594 (2015).","DOI":"10.1136\/bmj.g7594"},{"issue":"1","key":"49648_CR43","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.pec.2013.12.016","volume":"95","author":"B Sansbury","year":"2014","unstructured":"Sansbury, B., Dasgupta, A., Guthrie, L. & Ward, M. Time perspective and medication adherence among individuals with hypertension or diabetes mellitus. Patient Educ. Couns. 95 (1), 104 (2014).","journal-title":"Patient Educ. Couns."},{"key":"49648_CR44","doi-asserted-by":"crossref","unstructured":"Shi, L., Zhang, J. & Deng, Y. Associations of pretreatment emotional distress with adherence to therapy for patients with locally advanced rectal cancer: a post hoc analysis of the Chinese FOWARC phase 3 randomized clinical trial. BMC Med. 23(1), 293 (2025).","DOI":"10.1186\/s12916-025-04128-5"},{"issue":"2","key":"49648_CR45","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4103\/aort.aort_17_21","volume":"1","author":"MD Kaur","year":"2021","unstructured":"Kaur, M. D. et al. Health-related quality of life of patients after breast cancer treatment. Ann. Oncol. Res. Ther. 1 (2), 91\u201399 (2021).","journal-title":"Ann. Oncol. Res. Ther."},{"issue":"15_suppl","key":"49648_CR46","doi-asserted-by":"publisher","first-page":"e19519","DOI":"10.1200\/JCO.2017.35.15_suppl.e19519","volume":"35","author":"B Ung","year":"2017","unstructured":"Ung, B. et al. Adherence, quality of life, health care resource use, and functional impairment among patients with oral multiple myeloma (MM) treatments. J. Clin. Oncol. 35 (15_suppl), e19519\u2013e19519 (2017).","journal-title":"J. Clin. Oncol."},{"key":"49648_CR47","doi-asserted-by":"crossref","unstructured":"Bahrami, M., Mohamadirizi, M., Mohamadirizi, S. & Hosseini, S. A. Evaluation of body image in cancer patients and its association with clinical variables. J. Educ. Health Promot. 6(1), 81 (2017).","DOI":"10.4103\/jehp.jehp_4_15"},{"key":"49648_CR48","doi-asserted-by":"crossref","unstructured":"Hamdeh, N. A. et al. Predictors of quality of life in multiple myeloma patients: a multi-centered cross- sectional study. BMC Cancer.  25(1),1472 (2025).","DOI":"10.1186\/s12885-025-14960-w"},{"issue":"9","key":"49648_CR49","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","volume":"22","author":"MA Dimopoulos","year":"2025","unstructured":"Dimopoulos, M. A. et al. EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat. Rev. Clin. Oncol. 22 (9), 680\u2013700 (2025).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"49648_CR50","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","volume":"31","author":"SZ Usmani","year":"2025","unstructured":"Usmani, S. Z. et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Nat. Med. 31 (4), 1195\u20131202 (2025).","journal-title":"Nat. Med."},{"issue":"21","key":"49648_CR51","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.3390\/cancers17213587","volume":"17","author":"I Amitai","year":"2025","unstructured":"Amitai, I. et al. High Implementation Adherence to Lenalidomide in Multiple Myeloma. Cancers (Basel). 17 (21), 3587 (2025).","journal-title":"Cancers (Basel)"},{"issue":"8","key":"49648_CR52","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17 (8), e328\u2013e346 (2016).","journal-title":"Lancet Oncol."},{"key":"49648_CR53","doi-asserted-by":"crossref","unstructured":"Fonseca, R. et al. Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review. Clin Lymphoma, Myeloma Leuk. ;23(6):426\u2013437.e11. (2023).","DOI":"10.1016\/j.clml.2023.03.005"},{"key":"49648_CR54","doi-asserted-by":"crossref","unstructured":"Forde, K., Cocks, K., Wells, J. R., McMillan, I. & Kyriakou, C. Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development. Blood Cancer J. 13(1), 79 (2023).","DOI":"10.1038\/s41408-023-00815-9"},{"issue":"8","key":"49648_CR55","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.6004\/jnccn.2020.7561","volume":"18","author":"AK Zaleta","year":"2020","unstructured":"Zaleta, A. K. et al. Symptom Burden, Perceived Control, and Quality of Life Among Patients Living With Multiple Myeloma. J. Natl. Compr. Canc Netw. 18 (8), 1087\u20131095 (2020).","journal-title":"J. Natl. Compr. Canc Netw."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49648-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49648-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49648-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T23:39:07Z","timestamp":1781480347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49648-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["49648"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-49648-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Approval for this study was obtained from the Institutional Review Board (IRB) at Palestine Polytechnic University, Hebron, Palestine. Prior to participation, all individuals were clearly informed about the purpose, methodology, possible risks, and anticipated benefits of the research, and each signed a written consent form. Participant confidentiality was rigorously preserved, and the study was conducted in accordance with the ethical standards of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"18468"}}